JAPAN —Japanese pharmaceutical company Shionogi & Co., Ltd. has announced that its Board of Directors approved an agreement to acquire IntraBio Inc. Under the terms of the signed agreement, IntraBio will become a wholly owned subsidiary of Shionogi's US-based unit, Shionogi Inc. The acquisition is subject to customary closing conditions and will transfer global intellectual property and commercialization rights for IntraBio's lead therapy, AQNEURSA (levacetylleucine), to Shionogi.
Shionogi & Co., Ltd. is a research-driven Japanese pharmaceutical company headquartered in Osaka that focuses on developing treatments for infectious diseases and central nervous system disorders. IntraBio Inc. is a US biopharmaceutical firm based in Austin, Texas, specializing in novel therapies for rare neurodegenerative and genetic neurological conditions.
The transaction centers on AQNEURSA, a drug approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for neurological manifestations of Niemann-Pick disease Type C. The therapy also received FDA approval in September 2026 for treating ataxia in patients with Ataxia-Telangiectasia, with a corresponding regulatory review currently underway by the EMA. Beyond AQNEURSA, the acquisition integrates IntraBio's clinical development pipeline for rare conditions including Pompe disease, Fragile X syndrome, and Jordan's syndrome into Shionogi's existing operations.
This strategic move highlights a broader trend among major Asian pharmaceutical manufacturers acquiring specialty biotech firms to build dedicated rare disease franchises. Following Shionogi's previous acquisition of global rights to amyotrophic lateral sclerosis treatment RADICAVA in April 2026, the deal establishes a broader footprint in neurology and orphan drugs. For healthcare providers, commercial insurers, and biopharmaceutical investors, the consolidation accelerates global commercial distribution for specialized treatments and strengthens research infrastructure in underserved neurodegenerative therapy areas.
